

Clinical Trial Protocol

Iranian Registry of Clinical Trials

18 Sep 2026

Investigation of the effect of Melatonin mouthwash on prevention of chemotherapy-induced oral mucositis, a randomized double blinded placebo controlled clinical trial

Protocol summary

Study aim

Investigation of the effect of Melatonin mouthwash on prevention of chemotherapy-induced oral mucositis, a randomized double blinded placebo controlled clinical trial.

Design

Phase III randomized, double-blind, placebo-controlled clinical trial will be conducted on 70 patients, using block randomization method to randomize the experiment.

Settings and conduct

Study site: Shahid Rajaei Educational and Medical center
The mouthwash bottles will be numbered according to the randomized list and by a person who was not involved in patient registry and examination of oral mucositis; all involved in patient registry and examination of oral mucositis will not be informed about the numbers related to drug or placebo during the study.

Participants/Inclusion and exclusion criteria

Entry requirements: Age 18 and above. A patient with malignant solid tumor and candidate for chemotherapy (receiving medications with potential of almost similar mucositis: Cyclophosphamide, Doxorubicin, Fluorouracil, Methotrexate, Gemcitabine, Dacarbazine, and Cisplatin). Karnofsky status greater than or equal to 60%. Oral and written satisfaction (consent) of patients to participate in survey. No entry requirements: Inability in using the mouthwash. Smoking. Increasing hypersensitivity to melatonin or any other components used in formulation. History of head and neck radiotherapy. Having any lesions inside the mouth.

Intervention groups

Patients within intervention group will receive 4 ml of 0.3% melatonin mouthwash three times a day, and the patients of the control group will use 4 ml of placebo mouthwash (without active ingredient of melatonin in the formulation) made in Alborz School of Pharmacy three times a day. The mouthwash will be used from the first

day of chemotherapy, for 6 weeks.

Main outcome variables

Intensity of mucositis

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20220213054015N1**

Registration date: **2022-04-12, 1401/01/23**

Registration timing: **prospective**

Last update: **2022-04-12, 1401/01/23**

Update count: **0**

Registration date

2022-04-12, 1401/01/23

Registrant information

Name

Aida Abdi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 3382 6525

Email address

abdiaida00@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2022-05-20, 1401/02/30

Expected recruitment end date

2022-09-21, 1401/06/30

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Investigation of the effect of Melatonin mouthwash on prevention of chemotherapy-induced oral mucositis, a randomized double blinded placebo controlled clinical trial

Public title

Investigation of the effect of Melatonin mouthwash on prevention of chemotherapy-induced oral mucositis

Purpose

Prevention

Inclusion/Exclusion criteria**Inclusion criteria:**

Age 18 and above. A patient with malignant solid tumor and candidate for chemotherapy (receiving medications with potential of almost similar mucositis: Cyclophosphamide, Doxorubicin, Fluorouracil, Methotrexate, Gemcitabine, Dacarbazine, and Cisplatin). Karnofsky status $\geq 60\%$. Oral and written satisfaction (consent) of patients to participate in survey.

Exclusion criteria:

Inability in using the mouthwash. Smoking. Increasing hypersensitivity to melatonin or any other components used in formulation. History of head and neck radiotherapy. Having any lesions inside the mouth.

AgeFrom **18 years** old**Gender**

Both

Phase

3

Groups that have been masked

- Participant
- Care provider
- Outcome assessor
- Data analyser

Sample sizeTarget sample size: **70****Randomization (investigator's opinion)**

Randomized

Randomization description

The patients will be randomly classified in two classes of melatonin and placebo using block randomization method (block of size 6), to randomize the experiment. The randomization sequence using a computer-based randomized list will be determined by a person not involved in patient registry, then the mouthwash bottles will be numbered according to the randomized list and by a person who was not involved in patient registry and examination of oral mucositis; anyone involved in patient registry and examination of oral mucositis will not be informed about the numbers related to drug or placebo during the study.

Blinding (investigator's opinion)

Double blinded

Blinding description

This study is double blinded clinical trial, which means the patient and the researcher who provide the drug or placebo to the patients and evaluate the patients, are not aware whether the mouthwash is a drug or placebo. for this purpose, after making melatonin mouthwash and placebo which will both be exactly the same in appearance, these mouthwashes are poured into totally the same bottles by a researcher who is not involved in patient recruitment and examination of oral mucositis; then they are numbered in blocks of 6 size on a list of random computer numbers. it is worth noting that this list and that each number belongs to drug or placebo, is only available to the senior researcher (supervisor) who is not involved in the patient recruitment and examination of oral mucositis. Then, these completely similar bottles, on which only one number is installed, are given to the student (person responsible for patient recruitment) so that the student can provide the bottles to the patients in the order of the number of patients who entering the study.

Placebo

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Alborz University of Medical Sciences

Street address

Safareyan St., Golshahr Ave.

City

Karaj

Province

Alborz

Postal code

3198764653

Approval date

2022-02-01, 1400/11/12

Ethics committee reference number

IR.ABZUMS.REC.1400.311

Health conditions studied**1****Description of health condition studied**

chemotherapy-induced oral mucositis

ICD-10 code**ICD-10 code description**

Primary outcomes

1

Description

Intensity of mucositis

Timepoint

At the beginning of the study (before initiating intervention), as well as, 7, 14, 21, 28, 35, and 42 days after using the melatonin mouthwash

Method of measurement

World Health Organization Toxicity Scale

Secondary outcomes

1

Description

Intensity of pain

Timepoint

At the beginning of the study (before initiating intervention), as well as, 7, 14, 21, 28, 35, and 42 days after using the melatonin mouthwash.

Method of measurement

Visual analog scale

2

Description

Quality of Life

Timepoint

At the beginning of the study (before initiating intervention), as well as, 7, 14, 21, 28, 35, and 42 days after using the melatonin mouthwash

Method of measurement

EORTC Quality of Life Questionnaire QLQ-C30

Intervention groups

1

Description

Intervention group: Patients will gargle 4 ml of melatonin mouthwash made in Alborz School of Pharmacy, three times a day (a measuring cup with defined volume will be provided to facilitate the use). The patients will be asked to keep the mouth wash in their mouth for a minute or as long as possible, before spitting out. The patients will be asked to avoid eating for the next 30 min after using the mouthwash. The mouthwash will be utilized from the first day of chemotherapy and will continue for the next 6 weeks. The purpose and advantages of this survey will be thoroughly explained to the patients to ensure the consistent use of mouthwash through the survey; patients will also be inquired to join the survey in case of possible consistent accompaniment and complete consent. The practice of mouthwash by the patients will regularly be monitored via telephone calls or social media. It should be noted that some errors might inevitably emerge during the survey.

Category

Prevention

2

Description

Control group: Patients will gargle 4 ml of placebo mouthwash made in Alborz School of Pharmacy (without melatonin active ingredient in mouthwash formulation) three times a day (a measuring cup with defined volume will be provided to facilitate the use). The patients will be asked to keep the mouth wash in their mouth for a minute or as long as possible, before spitting out. The patients will be asked to avoid eating for the next 30 min after using the mouthwash. The mouthwash will be utilized from the first day of chemotherapy and will continue for the next 6 weeks. The purpose and advantages of this survey will be thoroughly explained to the patients to ensure the consistent use of mouthwash through the survey; patients will also be inquired to join the survey in case of possible consistent accompaniment and complete consent. The practice of mouthwash by the patients will regularly be monitored via telephone calls or social media. It should be noted that some errors might inevitably emerge during the survey.

Category

Prevention

Recruitment centers

1

Recruitment center

Name of recruitment center

Shahid Rajaei Educational and Medical Center

Full name of responsible person

Aida Abdi

Street address

Shahid Rajaei St., Hesarak.

City

Karaj

Province

Alborz

Postal code

3197635141

Phone

+98 26 3457 0030

Email

Rajaei@abzums.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Karaj University of Medical Sciences

Full name of responsible person

Deputy of research and technology

Street address

Safareyan St., Glshahr Ave.

City

Karaj

Province

Alborz

Postal code
3198764653

Phone
+98 26 3464 3705

Email
Research@abzums.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?
Yes

Title of funding source
Karaj University of Medical Sciences

Proportion provided by this source
100

Public or private sector
Public

Domestic or foreign origin
Domestic

Category of foreign source of funding
empty

Country of origin

Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact

Name of organization / entity
Karaj University of Medical Sciences

Full name of responsible person
Elliyeh Ghadrddan

Position
Assistant Professor

Latest degree
Ph.D.

Other areas of specialty/work
Medical Pharmacy

Street address
School of Pharmacy, Next to Bamonar Hospital, Vali-ye-Asr St., Shura Blvd., Azimieh, Karaj, Alborz Province

City
Karaj

Province
Alborz

Postal code
3154686689

Phone
+98 26 3256 7175

Fax

Email
EL.ghardan@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity
Karaj University of Medical Sciences

Full name of responsible person
Elliyeh Ghadrddan

Position

Assistant Professor

Latest degree
Ph.D.

Other areas of specialty/work
Medical Pharmacy

Street address
School of Pharmacy, Next to Bamonar Hospital, Vali-ye-Asr St., Shura Blvd., Azimieh, Karaj, Alborz Province

City
Karaj

Province
Alborz

Postal code
3154686689

Phone
+98 26 3256 7175

Fax

Email
EL.ghardan@gmail.com

Person responsible for updating data

Contact

Name of organization / entity
Karaj University of Medical Sciences

Full name of responsible person
Aida Abdi

Position
Student

Latest degree
A Level or less

Other areas of specialty/work
Medical Pharmacy

Street address
School of Pharmacy, Next to Bamonar Hospital, Vali-ye-Asr St., Shura Blvd., Azimieh, Karaj, Alborz Province

City
Karaj

Province
Alborz

Postal code
3154686689

Phone
+98 21 3382 6525

Fax

Email
abdiaida00@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available

Study Protocol
Yes - There is a plan to make this available

Statistical Analysis Plan
Yes - There is a plan to make this available

Informed Consent Form
Yes - There is a plan to make this available

Clinical Study Report
Yes - There is a plan to make this available

Analytic Code
Not applicable

Data Dictionary

Not applicable

Title and more details about the data/document

All collected data.

When the data will become available and for how long

After the end of the study and its publication.

To whom data/document is available

Researchers.

Under which criteria data/document could be used

Use for review studies.

From where data/document is obtainable

Corresponding author email.

What processes are involved for a request to access data/document

Sending email.

Comments